News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biomanufacturing costs and the risk of extractables and leachables can be reduced by developing more compatible plastics, Sabic told Biopharma-Reporter.com at CPhI in Paris.
US academics have licensed a mobile clean room design from Xoma for a vaccine and medical countermeasure plant being built in Texas as part of an HHS-funded project.
Fujifilm has launched a mammalian cell line it says can deliver titers up to 3g/L before subsequent optimisation and will complement its microbial-based platform.
Biosimilars company Pfenex is about to set to start a large research programme into recombinant protein vaccines with the non-profit PATH.